{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["50(7)"],"submitter":["Xie XF"],"pubmed_abstract":["The efficacy and tolerability of eribulin mesylate, a synthetic halichondrin B analog, in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes have been established. Acute-on-chronic liver failure (ACLF) is a clinical syndrome manifesting as acute and severe hepatic derangement resulting from varied insults in patients with established chronic liver disease or cirrhosis who did not previously receive eribulin. A middle-aged woman diagnosed with MBC and diffuse liver metastases who was pretreated with multi-line chemotherapy received eribulin as eighth-line chemotherapy and presented with hepatic encephalopathy, rapid bilirubin elevation, and significant coagulation dysfunction on day 4 in cycle 1. The patient was diagnosed with ACLF induced by eribulin. Therefore, ACLF may be a lethal and rare adverse event when patients with chronic liver metastases receive eribulin treatment, and clinicians' awareness should be increased for optimal prevention and prompt diagnosis and treatment."],"journal":["The Journal of international medical research"],"pagination":["3000605221090097"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9340925"],"repository":["biostudies-literature"],"pubmed_title":["Acute-on-chronic liver failure following eribulin treatment for metastatic breast cancer: a case report."],"pmcid":["PMC9340925"],"pubmed_authors":["Song L","Du CW","Huang JY","Zhang QY","Xie XF","Lan XF","Chen LP","Bai X"],"additional_accession":[]},"is_claimable":false,"name":"Acute-on-chronic liver failure following eribulin treatment for metastatic breast cancer: a case report.","description":"The efficacy and tolerability of eribulin mesylate, a synthetic halichondrin B analog, in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes have been established. Acute-on-chronic liver failure (ACLF) is a clinical syndrome manifesting as acute and severe hepatic derangement resulting from varied insults in patients with established chronic liver disease or cirrhosis who did not previously receive eribulin. A middle-aged woman diagnosed with MBC and diffuse liver metastases who was pretreated with multi-line chemotherapy received eribulin as eighth-line chemotherapy and presented with hepatic encephalopathy, rapid bilirubin elevation, and significant coagulation dysfunction on day 4 in cycle 1. The patient was diagnosed with ACLF induced by eribulin. Therefore, ACLF may be a lethal and rare adverse event when patients with chronic liver metastases receive eribulin treatment, and clinicians' awareness should be increased for optimal prevention and prompt diagnosis and treatment.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2024-10-17T18:57:57.695Z","creation":"2024-10-17T18:57:57.695Z"},"accession":"S-EPMC9340925","cross_references":{"pubmed":["35899681"],"doi":["10.1177/03000605221090097"]}}